Tarsus Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TARS research report →
Companywww.tarsusrx.com
Tarsus Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
- CEO
- Bobak R. Azamian
- IPO
- 2020
- Employees
- 323
- HQ
- Irvine, CA, US
Price Chart
Valuation
- Market Cap
- $2.79B
- P/E
- -57.66
- P/S
- 5.21
- P/B
- 7.98
- EV/EBITDA
- -70.92
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 90.44%
- Op Margin
- -9.50%
- Net Margin
- -9.02%
- ROE
- -14.19%
- ROIC
- -11.54%
Growth & Income
- Revenue
- $451.36M · 146.71%
- Net Income
- $-66,418,000 · 42.52%
- EPS
- $-1.59 · 48.21%
- Op Income
- $-70,969,000
- FCF YoY
- 73.63%
Performance & Tape
- 52W High
- $85.25
- 52W Low
- $38.51
- 50D MA
- $66.28
- 200D MA
- $67.40
- Beta
- 0.53
- Avg Volume
- 620.62K
Get TickerSpark's AI analysis on TARS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 24, 26 | PYOTT DAVID E I | other | 1,383 |
| Apr 24, 26 | PYOTT DAVID E I | other | 1,383 |
| Mar 20, 26 | Neervannan Seshadri | sell | 2,989 |
| Mar 17, 26 | Whitfield Dianne C. | sell | 4,029 |
| Mar 18, 26 | Whitfield Dianne C. | sell | 4,071 |
| Mar 19, 26 | Whitfield Dianne C. | sell | 4,174 |
| Mar 17, 26 | Wahl Bryan | sell | 4,084 |
| Mar 18, 26 | Wahl Bryan | sell | 4,125 |
| Mar 19, 26 | Wahl Bryan | sell | 4,231 |
| Mar 17, 26 | Neervannan Seshadri | sell | 3,125 |
Our TARS Coverage
We haven't published any research on TARS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TARS Report →